Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy

Drug resistance is the major cause for disease relapse and patient death in multiple myeloma (MM). It is an urgent need to develop new therapies to overcome drug resistance in MM. Chidamide (CHI), a novel oral HDAC inhibitor targeting HDAC1, 2, 3 and 10, has shown potential therapeutic effect in MM....

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yanjuan, Jiang, Duanfeng, Zhang, Kaixuan, Zhu, Yinghong, Zhang, Jingyu, Wu, Xuan, Xia, Jiliang, Zhu, Yan, Zou, Lang, Hu, Jian, Cui, Yajuan, Zhou, Wen, Chen, Fangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425211/
https://www.ncbi.nlm.nih.gov/pubmed/34539893
http://dx.doi.org/10.7150/jca.61602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425211/
https://www.ncbi.nlm.nih.gov/pubmed/34539893
http://dx.doi.org/10.7150/jca.61602

Ejemplares similares